Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Carcinogenesis

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Carcinogenesis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Brittain, GV; Frommeyer, TC; Gilbert, MM; Nguyen, TQ; Rohan, CA; Travers, JB; Wu, T1
He, X; He, Z; Hu, J; Ke, J; Lan, P; Li, S; Lian, L; Sun, L; Wu, X; Zou, Y1

Reviews

1 review(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Carcinogenesis

ArticleYear
UVB-Induced Microvesicle Particle Release and Its Effects on the Cutaneous Microenvironment.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Carcinogenesis; Humans; Keratinocytes; Platelet Activating Factor; Skin; Tumor Microenvironment; Ultraviolet Rays

2022

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Carcinogenesis

ArticleYear
PAF receptor antagonist Ginkgolide B inhibits tumourigenesis and angiogenesis in colitis-associated cancer.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:1

    Topics: Animals; Azoxymethane; Carcinogenesis; Colitis; Dextran Sulfate; Female; Ginkgolides; Lactones; Mice; Neovascularization, Pathologic; Plant Extracts; Platelet Activating Factor

2015